seeds could hinderthetimelyavailability ofthevaccines.
production.Nonetheless,thetimeittakestogenerateappropriate
originating wild-type virus before they can be used for vaccine
be confirmed for both genetic and antigenic match with their
Indeed,aspercurrentregulatoryrequirements,seedvirusesmust
lowduetothestringentqualitycontroloftheworkingseedvirus.
adaptation ofseedvirus duringvaccine manufacturing todayare
The chances of introducing deleterious mutations through the
efficiently recognised the glycosylated clade 3C.2a H3N2 virus26.
glycosylation site induced optimal levels of antibodies that
derived vaccines and as expected, rHA containing the new
glycosylated clade 3C.2a H3N2 strain26. Contrary to the egg-
bodies induced in humans, and in ferrets, poorly neutralised the
site was absent in the egg-adapted virus. Consequently, anti-
thenewglycosylationsite26.However,thisparticularglycosylation
a clade 3C.2a H3N2 strain (A/Colorado/15/2014) containing
2016–2017 season,theinfluenzavaccinewasupdated toinclude
a new predicted HA glycosylation site emerged26. For the
2014–2015influenzaseason,aclade3C.2aH3N2strainpossessing
contributed to this reduced vaccine effectiveness26. During the
vaccine strains and circulating strains are thought to have